Average Dose-Volume Ratio

Slides:

Advertisements

Similar presentations

Background/Purpose ATRT is a rare and aggressive CNS tumor usually presenting in very young children (age less than 5 years). Aggressive treatments have.

Advertisements

A phase I dose escalating study of intensity modulated radiation therapy (IMRT) for the treatment of glioblastoma multiforme (GBM) ( #1008) V. Stieber.

Danny Indelicato, MD CTOS 2012 Ewing Sarcoma of the Axial Skeleton: Early Outcomes from the University of Florida Proton Therapy Program.

Background:  IMRT has become the choice of treatment for disease sites that require critical structure sparing such as head and neck cancer.  It has.

1 Improved critical structure sparing with biologically based IMRT optimization X.Sharon Qi, Vladimir A. Semenenko and X. Allen Li Department of Radiation.

Stereotactic Body Radiation Therapy (SBRT): The optimal indication for operable tumors in inoperable patients D.Katsochi 1, S.Kosmidis 1, A.Fotopoulou.

The Health Roundtable 1-1b_HRT1215-Session_HEGI_JOHNSON_WESTMEAD_NSW Volumetric Modulated Arc Therapy for Stereotactic Body Radiotherapy in Early Lung.

Shannon M MacDonald 1, Salahuddin Ahmad 2, Stefanos Kachris 3, Betty J Vogds 2, Melissa DeRouen 3, Alicia E Gitttleman 3, Keith DeWyngaert 3, Maria T Vlachaki.

The external beam radiotherapy and Image-guided radiotherapy (2)

Measurement of Dose to Critical Structures Surrounding the Prostate from Intensity-Modulated Radiation Therapy (IMRT) and Three Dimensional Conformal Radiation.

Comparison of Rectal Dose Volume Histograms for Definitive Prostate Radiotherapy Among Stereotactic Radiotherapy, IMRT, and 3D-CRT Techniques Author(s):

INTRODUCTION  The majority of clinical trials addressing outcomes in limited- stage small cell lung cancer (LS-SCLC) following definitive chemoradiotherapy.

H Ariyaratne1,2, H Chesham2, J Pettingell2, K Sikora2, R Alonzi1,2

Clinico-Dosimetric Correlation for Acute and Chronic Gastrointestinal Toxicity in Patients of Locally Advanced Carcinoma Cervix Treated With Conventional.

Investigation of 3D Dosimetry for an Anthropomorphic Spine Phantom R. Grant 1,2, G. Ibbott 1, J. Yang 1, J. Adamovics 3, D Followill 1 (1)M.D. Anderson.

Introduction The Radiological Physics Center (RPC) anthropomorphic quality assurance (QA) phantom program is one tool the RPC uses to remotely audit institutions.

Optimization of Volumetric Modulated Arc Therapy (VMAT) Planning Strategy Using Ring-shaped ROI for Localized Prostate cancer Kentaro Ishii, Masako Hosono,

A Proton Therapy Overview Richard Eckart And David Turberville Richard Eckart And David Turberville.

Saad El Din I, M.D *, Abd El AAl H, M.D *, Makaar W, M.D *, El Beih D, M.Sc †, Hashem W, M.Sc * *Department of Clinical Oncology and Radiotherapy, Kasr.

Reducing excess imaging dose to cancer patients receiving radiotherapy Adam Schwertner, Justin Guan, Xiaofei Ying, Darrin Pelland, Ann Morris, Ryan Flynn.

Pencil Beam Scanning Proton Therapy for Lymphoma Patients with Mediastinal Involvement: A Dosimetric Study and Preliminary Clinical Data K. Dedeckova 1,

Proton Therapy Patterns-of-Care and Early Outcomes for Hodgkin Lymphoma: Results from the Proton Collaborative Group Registry Bradford Hoppe MD, MPH William.

Management of independent motion between multiple targets in lung cancer radiation therapy Feng Liu, PhD, An Tai, PhD, Ergun Ahunbay, PhD, Elizabeth.

John Boyle, MD, Brad Ackerson, MD, Lin Gu, MS, Chris R. Kelsey, MD

Feasibility of hippocampal sparing radiation therapy for glioblastoma using helical Tomotherapy Dr Kamalram THIPPU JAYAPRAKASH1,2,3, Dr Raj JENA1,4 and.

Introduction Materials & Methods Results Conclusion

Evaluation Of RTOG Guidelines For Monte Carlo Based Lung SBRT Planning

Evaluation of the AAA Treatment Planning Algorithm for SBRT Lung Treatment: Comparison with Monte Carlo and Homogeneous Pencil Beam Dose Calculations

Comparison of carina- versus bony anatomy-based registration for setup verification in esophageal cancer image-guided radiotherapy Melanie Machiels* 1,

Implementation of Object Spot Avoidance in Proton Pencil Beam Treatment on Whole Breast with Implant Metal Injector Peng Wang, PhD, DABR, Karla Leach,

Fig. 4. Percentage of passing rate between clinical and 544 plans.

Reducing Treatment Time and MUs by using Dynamic Conformal Arc Therapy for SBRT Breath-Hold Patients Timothy Miller, Sebastian Nunez Albermann, Besil Raju,

VMAT-technique (volumetric modulated arc therapy), IMRT-technique (intensity modulated radiotherapy) and 3D-conformal radiation for Lymphomas in Radiation.

Insert tables Insert figure

Insert tables Insert graphs Insert figure

Median Volume (cc) of GTV Receiving Dose

Volumetric Modulated Arc Therapy (VMAT) versus Intensity Modulated Radiation Therapy (IMRT) for Anal Carcinoma Heather Ortega, BSRT(T), CMD, Kerry Hibbitts,

Dosimetry of Alternative Techniques for Accelerated Partial Breast Irradiation Hanh Pham, B.S, CMD, Thanh Nguyen, BS, Christina Henson, MD, Salahuddin.

Insert tables Insert graphs Insert figure

Radiation Oncology Department, Bank of Cyprus Oncology Center.

Intensity-Modulated Radiotherapy After Extrapleural Pneumonectomy in the Combined- Modality Treatment of Malignant Pleural Mesothelioma Alexander Chi,

A Multi-Institutional Dosimetric Evaluation of Proton Versus Photon Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma F. Khan, B. Nguyen,

Postoperative Proton Therapy in the Management of Stage III Thymoma

Heart Dose Is an Independent Dosimetric Predictor of Overall Survival in Locally Advanced Non–Small Cell Lung Cancer Christina K. Speirs, MD, PhD, Todd.

Cornelis J. A. Haasbeek, MD, PhD, Frank J. Lagerwaard, MD, PhD, Ben J

Results of a Multicentric In Silico Clinical Trial (ROCOCO): Comparing Radiotherapy with Photons and Protons for Non-small Cell Lung Cancer Erik Roelofs,

Phantom Verification of AAA and Acuros Dose Calculations for Lung Cancer: Do Tumor Size and Regression Matter? Satomi Shiraishi, PhD, Luis E. Fong de.

Intensity-Modulated Radiotherapy for Lung Cancer: Current Status and Future Developments Clara Chan, MD, Stephanie Lang, MSc, Carl Rowbottom, PhD, Matthias.

Stereotactic Ablative Radiotherapy for Centrally Located Early Stage Non–Small-Cell Lung Cancer: What We Have Learned Joe Y. Chang, MD, PhD, Andrea Bezjak,

Multi-Institutional Prospective Study of Reirradiation with Proton Beam Radiotherapy for Locoregionally Recurrent Non–Small Cell Lung Cancer Hann-Hsiang.

Improved Overall Survival with Aggressive Primary Tumor Radiotherapy for Patients with Metastatic Esophageal Cancer David M. Guttmann, MD, MTR, Nandita.

Toxicities of Organs at Risk in the Mediastinal and Hilar Regions Following Stereotactic Body Radiotherapy for Centrally Located Lung Tumors Shuichi.

Kiran Devisetty, MD, Joseph K. Salama, MD Journal of Thoracic Oncology

Technical Advances of Radiation Therapy for Thymic Malignancies

ITV-Based Robust Optimization for VMAT Planning of Stereotactic Body Radiation Therapy of Lung Cancer Xiaoying Liang, PhD, Dandan Zheng, PhD, Maria Mamalui-Hunter,

Innovations in the Radiotherapy of Non–Small Cell Lung Cancer

Technical Innovations and Patient Support in Radiation Oncology

Patterns of Failure, Toxicity, and Survival after Extrapleural Pneumonectomy and Hemithoracic Intensity-Modulated Radiation Therapy for Malignant Pleural.

Stereotactic Body Radiation Therapy for Primary Lung Cancers >3 Centimeters John J. Cuaron, MD, Ellen D. Yorke, PhD, Amanda Foster, BA, Meier Hsu, MS,

Hemithoracic Radiotherapy After Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma: A Dosimetric Comparison of Two Well-Described Techniques

Clinical Intensity Modulated Proton Therapy for Hodgkin Lymphoma: Which Patients Benefit the Most? Georgios Ntentas, DPhil, Katerina Dedeckova, MD, Michal.

Patterns of Local and Nodal Failure in Malignant Pleural Mesothelioma After Extrapleural Pneumonectomy and Photon-Electron Radiotherapy Vishal Gupta,

Whole-ventricular irradiation for intracranial germ cell tumors: Dosimetric comparison of pencil beam scanned protons, intensity-modulated radiotherapy.

Todd J. Carpenter, MD, Kenneth E. Rosenzweig, MD

Jesse Conterato, BA&Sc. RSNA 2016

William Hartsell, M.D. Medical Director

Proton Therapy for Thymic Malignancies: Multi-institutional Patterns-of-Care and Early Clinical Outcomes from the Proton Collaborative Group Registry &

Bradford Hoppe MD, MPH William Hartsell, MD

Proton Beam Therapy for Liver Cancer is Well Tolerated: Outcomes from the Proton Collaborative Group REG Trial Michael Chuong, M.D.1,2, Smith Apisarnthanarx,

Planning techniques of proton boost

Presentation transcript:

Average Dose-Volume Ratio Dosimetric Comparisons of Uniform Scanning Proton Beam Therapy (US PBT) versus Intensity Modulated Radiation Therapy (IMRT) for Mediastinal Malignancies. John Han-Chih Chang, MD3, Shae Gans, CMD1, Mark Pankuch, PhD2, Kim Hahn4, Lori Abruscato3, and William Hartsell, MD3 From the Departments of Medical Dosimetry1, Physics2, and Radiation Oncology3, CDH Proton Center – A ProCure Center and the CDH Cancer Center, Warrenville, IL, USA, and the Proton Collaborative Group4, Bloomington, IL, USA Introduction: Thoracic radiotherapy has been an essential component of treatment for various neoplasms of the mediastinum. However, for the survivors of such malignancies, this has levied significant toxicities both acute and long term on to the adjacent thoracic normal tissues, such as the heart/ pericardium, left ventricle, esophagus, and normal lung parenchyma. We evaluated and compared the dosimetric treatment plans of patients receiving mediastinal radiation therapy at our proton center. Results: The target volume coverage was similar between the US PBT and the IMRT plans. The V98 and V95 for the PTV were 98% and 100%, respectively, with either modality. However, the treatment planning data revealed a statistically significant increase in the V5 and mean dose to the left ventricle and total heart with IMRT over US PBT. There was also a significant 33% increase in the mean dose to the esophagus with IMRT plan. The lung V5 was slightly more than double in the IMRT plans, in addition to the lung V20 and mean dose being approximately 65-84% higher with IMRT. 1a 1b Methods and Materials: We evaluated our most recent 10 patients treated for lymphoma, thymoma, or sarcoma involving and requiring radiation therapy to the mediastinum. Mean dose to the primary tumor or tumor bed was 41.66 Gray. The IMRT plan utilized the EclipseTM planning software and incorporated 6 MV photons with coplanar beams and a single isocenter, while the US PBT was planned using the XiOTM treatment planning system. Target volumes (GTV/CTV and PTVs) along with normal tissue volumes contoured for each planning system were identical. Dose volume histograms/parameters were reviewed and compared. We evaluated the data as an individual dose or volume ratio for each patient/parameter and then averaged the ratio. We also took the summation of all the patients’ treatment planning parameter values and obtained overall average dose-volume ratios to determine the statistical significance. Dose-Volume Ratio Average Dose-Volume Ratio P value Left Ventricle V5 4.93 2.23 0.018 Left Ventricle V20 5.54 1.33 0.206 Left Ventricle Mean Dose 4.81 1.75 0.012 Total Heart V5 1.52 1.45 0.035 Total Heart Mean Dose 1.17 1.21 0.044 Esophagus Mean Dose 5.38 0.004 Lung V5 1.94 2.08 < 0.001 Lung V20 1.46 1.65 0.036 Lung Mean Dose 1.84 Figure 1: Axial view comparisons of isodose lines for consolidative radiation treatment of Hodgkin’s Lymphoma with IMRT (a) and US PBT (b). 2a Table 1: Dosimetric-Volumetric Ratios of IMRT/US PBT Conclusion: We have demonstrated the feasibility of US PBT in the situation of mediastinal irradiation as it has clear advantages over IMRT in the distribution of radiation dose to the target regions with exposure minimization to the thoracic normal tissue structures. This will segway into our prospective study, which evaluates the toxicities and quality of life metrics during and post US PBT for mediastinal malignancies. 2b Figure 2: Sagittal view comparisons of isodose lines for consolidative radiation treatment of Hodgkin’s Lymphoma with IMRT (a) and US PBT (b).